Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haim Matzkin

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
BJU International|February 12, 2005
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunctionR Jeroen A van Moorselaar, Rudolf Hartung, Mark Emberton, et al.
Urology|October 20, 2004
Refinements in treatment of large bladder calculi: simultaneous percutaneous suprapubic and transurethral cystolithotripsyMario Sofer, Issac Kaver, Alexander Greenstein, et al.
BJU International|March 7, 2008
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practiceGuy Vallancien, Mark Emberton, Antonio Alcaraz, et al.
Journal of Endourology|March 16, 2017
Upper Calyx Accessibility Through a Lower Calyx Access Is Not Influenced by Morphometric and Clinical Factors in Supine Percutaneous NephrolithotomyMario Sofer, Yazeed Barghouthy, Yuval Bar-Yosef, et al.
BJU International|February 14, 2006
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practiceMostafa Elhilali, Mark Emberton, Haim Matzkin, et al.
Urology|October 2, 2007
Extending the application of tubeless percutaneous nephrolithotomyMario Sofer, Avi Beri, Alan Friedman, et al.
Urologic Oncology|August 12, 2020
The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings-Implications for the COVID-19 eraZiv Savin, Snir Dekalo, Ron Marom, et al.
Cancer Biology & Therapy|June 1, 2012
HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patientsMichael Vainrib, Maya Golan, Sharon Amir, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 16, 2006
RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patientsAvi Orr-Urtreger, Anat Bar-Shira, Dani Bercovich, et al.
European Urology Focus|July 30, 2017
A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation StudyNoa Davis, Alexander Shtabsky, Sylvia Lew, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
BJU International|February 12, 2005
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunctionR Jeroen A van Moorselaar, Rudolf Hartung, Mark Emberton, et al.
Urology|October 20, 2004
Refinements in treatment of large bladder calculi: simultaneous percutaneous suprapubic and transurethral cystolithotripsyMario Sofer, Issac Kaver, Alexander Greenstein, et al.
BJU International|March 7, 2008
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practiceGuy Vallancien, Mark Emberton, Antonio Alcaraz, et al.
Journal of Endourology|March 16, 2017
Upper Calyx Accessibility Through a Lower Calyx Access Is Not Influenced by Morphometric and Clinical Factors in Supine Percutaneous NephrolithotomyMario Sofer, Yazeed Barghouthy, Yuval Bar-Yosef, et al.
BJU International|February 14, 2006
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practiceMostafa Elhilali, Mark Emberton, Haim Matzkin, et al.
Urology|October 2, 2007
Extending the application of tubeless percutaneous nephrolithotomyMario Sofer, Avi Beri, Alan Friedman, et al.
Urologic Oncology|August 12, 2020
The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings-Implications for the COVID-19 eraZiv Savin, Snir Dekalo, Ron Marom, et al.
Cancer Biology & Therapy|June 1, 2012
HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patientsMichael Vainrib, Maya Golan, Sharon Amir, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 16, 2006
RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patientsAvi Orr-Urtreger, Anat Bar-Shira, Dani Bercovich, et al.
European Urology Focus|July 30, 2017
A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation StudyNoa Davis, Alexander Shtabsky, Sylvia Lew, et al.
Pageof 8